Introduction: There have been a variety of reports in the U. S. and Europe on the relationship between depression and HIV infection, including the effects of depression on disease progress and mortality rates, but the results have been inconclusive. In Japan there have been fewer reports that have statistically analyzed the mental states of multiple patients with HIV infection. Therefore, we used a simple, self-rating depression scale (SDS) to study the prevalence of depression among HIV-infected persons visiting our outpatient clinic.
Subjects and Methods: We conducted a cross-sectional study of 40 HIV-infected patients visiting our outpatient clinic. We interviewed patients whose total SDS scores were 40 or more, using the Major Depression Episode criteria in mini international neuropsychiatric interview (MINI). We conducted the same procedure on 40 patients who were visiting our outpatient clinic for reasons other than HIV infection; these patients formed the control group.
Results: Eighteen patients had SDS scores of 40 or more. One of these was assessed as having major depression and 4 were determined to have minor depression. A total of 5 patients (12.5% of the subject group) were assessed as having depression. In the control group, 5.0% were judged as having depression. Significantly more patients taking efavirenz had depression than those not taking efavirenz (
P=0.015: chi-squared test). Differences in infection route, nationality, number of CD4-positive cells, HIV-RNA level, and HAART regimen were not significantly correlated with differences in prevalence of depression.
Conclusion: There was a significantly greater rate of depression among HIV patients taking efavirenz, suggesting that caution is needed when administering this drug to depressed patients. It may be advisable to conduct depression tests such as the SDS on patients who are to be treated with efavirenz.
View full abstract